However, their limitations include high equipment costs, difficulty distinguishing D‐2HG from its chiral enantiomer, and inability to spatially and quantitatively access the IDH1 mutational heterogenicity in glioma samples. The gene discussed is IDH1; the disease is central nervous system cancer.